Yesterday, Halberd Corporation (OTC PINK: HALB) stock closed up 41.41 percent, closing at $0.0700, and has been fluctuating between $0.0509 and $0.0740 during the trading session. In the last month, HALB stock soared over 79.49% while reaching over 180.00% in three months. The Halberd Corporation stock has seen a 13500.00% gain in the last year, with a high of $0.0930 and a market cap of $27.46M.
Following the announcement last week of a patent protection initiative that caught the attention of investors especially on social platforms, the Halberd stock price rallied for the third consecutive day.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
- Top 3 Cybersecurity Stocks You Should Keep on your Watch List
- Top 3 Cloud Computing Stocks to Watch For in 2021
What was the objective?
Listed on the OTC Market, Halberd Corporation conforms fully to the reporting requirements of the OTC-Market. There are no outstanding debts, and HALB owns the exclusive rights to COVID-19 extracorporeal treatments.
An application of the International Patent Cooperation Treaty (PCT) titled “Method for Treating and Curing Covid-19 Infection” was recently filed by Halberd Corporation.
There are currently over 150 participating countries in this Agreement, allowing inventors to protect their innovations simultaneously in many countries.
Chairman, President & CEO of Halberd Corporation, William A. Hartman, stated that HALB believes this technology is sufficiently innovative to warrant patent protection in countries other than the United States. In many countries around the globe, HALB can protect its technology under the PCT. A patented extracorporeal process by Halberd could be used to treat Covid and other diseases through radiofrequency elimination thanks to research underway with GreenBioAZ and laser ablation methodologies being explored.
How are things going with the patent?
The U.S. provisional patent application of Halberd Corporation (HALB), “Method for Treating and Curing Covid-19 Infection” was initially filed with the U.S. Patent and Trademark Office on March 16, 2020. HALB holds an exclusive worldwide license to this technology.